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An open-label, one-arm, dose-
escalation study to evaluate safety 
and tolerability of extremely low 
frequency magnetic fields in acute 
ischemic stroke
Fioravante Capone1,2, Micaela Liberti  3, Francesca Apollonio3, Francesca Camera3, Stefania 
Setti4, Ruggero Cadossi4, Carlo Cosimo Quattrocchi  5 & Vincenzo Di Lazzaro1,2
Extremely low frequency magnetic fields (ELF-MF) could be an alternative neuroprotective approach 
for ischemic stroke because preclinical studies have demonstrated their effects on the mechanisms 
underlying ischemic damage. The purpose of this open-label, one arm, dose-escalation, exploratory 
study is to evaluate the safety and tolerability of ELF-MF in patients with acute ischemic stroke. Within 
48 hours from the stroke onset, patients started ELF-MF treatment, daily for 5 consecutive days. Clinical 
follow-up lasted 12 months. Brain MRI was performed before and 1 month after the treatment. The 
distribution of ELF-MF in the ischemic lesion was estimated by dosimetry. Six patients were stimulated, 
three for 45 min/day and three for 120 min/day. None of them reported adverse events. Clinical 
conditions improved in all the patients. Lesion size was reduced in one patient stimulated for 45 minutes 
and in all the patients stimulated for 120 minutes. Magnetic field intensity within the ischemic lesion 
was above 1 mT, the minimum value able to trigger a biological effect in preclinical studies. Our 
pilot study demonstrates that ELF-MF are safe and tolerable in acute stroke patients. A prospective, 
randomized, placebo-controlled, double-blind study will clarify whether ELF-MFs could represent a 
potential therapeutic approach.
Ischemic stroke is a leading cause of death and disability worldwide, bearing a deep impact on the socioeconomic 
burden for healthcare. To date, thrombolysis is the only approved treatment however, the time window is lim-
ited to the first hours after stroke, and thus there is an urgent need of different therapies capable to reduce the 
catastrophic consequences of brain ischemia beyond this short period of intervention. During stroke, acute dis-
ruption of blood flow causes pronounced deficit in oxygen and nutrients delivery leading to immediate neuronal 
death in the core of the ischemic region. Initially, the surrounding tissue, also called the “penumbra”, remains less 
affected and partially functioning; however, in the following hours, the occurrence of an inflammatory response, 
with the production of neurotoxic molecules may significantly enlarge the area of neuronal death. Thus, the 
ischemic penumbra represents the ideal target for neuroprotective strategies aiming to reduce brain ischemic 
damage1.
During the past decades, important advances have been made in better understanding the pathophysiolog-
ical mechanisms and the signaling pathways involved in the evolution of the ischemic penumbra. Converging 
evidence suggest that the purine nucleoside adenosine plays a key-role. Adenosine is an important local tissue 
function regulator, particularly when cellular energy supply fails to meet the demand such occurs in the ischemic 
conditions2. Extracellular adenosine concentrations increase dramatically soon after ischemia and adenosine 
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receptors located both on central nervous system cells and on immune blood cells exert important roles during 
ischemia and post-ischemic inflammation2. Thus, adenosine receptors could be potential targets for neuropro-
tection and experimental data support this hypothesis. In particular, it has been demonstrated that CGS21680 
agonist for the adenosine receptor A2A protects brain tissue in a rat model of transient medial cerebral artery 
occlusion3 by preventing leucocytes infiltration and neuroinflammation following brain ischemia4. Even though 
experimental studies have demonstrated that modulation of adenosine system could be a viable neuroprotective 
strategy for ischemic stroke, translation to humans has been hampered by the difficulties in producing molecules 
that selectively activate A2A receptors without inducing desensitization and downregulation and by the occur-
rence of adverse effects at dosages compatible with a therapeutic effect.
In 2002, for the first time, Varani et al. demonstrated the possibility of selectively modulate adenosine recep-
tors using a different strategy, alternative to drugs5. Indeed, they showed that a short exposure to extremely low 
frequency magnetic fields (ELF-MF) caused an upregulation of the A2A receptors expressed by blood cells5 and 
cortical neurons6. Subsequently, they demonstrated that the application of ELF-MF has also a direct protective 
effect on hypoxic damage in neuron-like cells and an anti-inflammatory effect in microglial cells7.
The neuroprotective potential of ELF-MF exposure has been also confirmed in animal studies. Grant et al.8 
demonstrated that ELF-MF stimulation attenuated brain damage both on magnetic resonance imaging (MRI) 
and on histologic examination in a rabbit model of transient focal ischemia. Pena-Philippides et al.9 confirmed 
these results in mice showing that such stimulation reduced the infarct size and induced anti-inflammatory and 
anti-apoptotic effects. Several studies have investigated the effects of ELF-MF in humans demonstrating that such 
stimulation is safe and can produce measurable effects in healthy volunteers10,11 but the effect of this stimulation 
has been never tested in stroke patients.
Our hypothesis is that ELF-MF could represent an innovative neuroprotective strategy for brain ischemia 
based on a more physiologic modulation of adenosine receptors because differently from drugs, magnetic stimu-
lation can induce tissue-specific agonist effects without any desensitization and downregulation.
The purpose of this exploratory study is to evaluate the safety and tolerability of ELF-MF in patients with 
acute ischemic stroke and to collect preliminary data about the interaction of such stimulation with human brain 
ischemic tissue.
We designed an open label, one arm, dose-escalation, exploratory study. The trial consisted of a 5-days inter-
vention phase and of a 12-months follow-up phase. Within 48 hours from the onset of the stroke, the enrolled 
patients have undergone clinical evaluation and brain MRI. Subsequently, the patients have undergone ELF-MF 
treatment, daily for 5 consecutive days. Clinical evaluations were repeated immediately, 30, 90, and 365 days after 
ELF-MF treatment. Brain MRI was repeated 30 days after ELF-MF treatment (Fig. 1).
Results
Seven patients (4 M; mean age: 76.3 ± 6.1) were recruited. One patient (F;85) withdrew the consent before the first 
session of stimulation, thus she was not considered in the analysis. According to the dose-escalation scheme, the 
first three patients were stimulated for 45 min/day and the following three patients for 120 min/day. Because we 
did not observe any adverse events (AEs), we propose to the following eligible patients an exposure of 240 min/
day but none of them accepted to participate. Indeed, such stimulation was considered too longer by the patients 
and potentially interfering with the standard of care for acute ischemic stroke by treating physicians. Six patients 
completed the 5-days treatment period and were included in the analysis. Among these, five patients completed 
the 12-months follow-up period while one patient was lost at the follow-up after the 3-months visit.
We did not observe any AE both during the treatment and during the follow-up phase. The vital parame-
ters (respiratory rate, heart rate, blood pressure, pulse oximetry, and ECG signal) remained stable during the 
ELF-MF stimulation. None of the patients required to stop treatment session or reported any discomfort created 
by ELF-MF stimulation.
Clinical conditions improved in all the patients (Table 1). Such improvement was slightly more evident in the 
group stimulated for a longer period (120 min). Table 2 shows the MRI volumetric measures of ischemic area, 
Figure 1. Study design. mRS: modfied Rankin scale. NIHSS: National Institutes of Health Stroke Scale. BI: 
Barthel Index. AEs: adverse events. SAEs: severe adverse events.
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assessed before and after ELF-MF treatment. In the group stimulated for 45 minutes, lesion volume at 1-month 
follow-up increased in two patients and reduced in one. In all the patients stimulated for 120 minutes, the volume 
of the ischemic lesion was reduced.
The distribution of magnetic field in the ischemic lesion and in the surrounding brain tissue was estimated 
by dosimetry simulation studies. Figure 2 shows the results of a representative patient in the whole head, in the 
ischemic region and in three slices of the ischemic volume at growing distances from the coil center. For each 
patient, we have calculated the distances of the ischemic lesion from the stimulating coil and the consequent 
induced magnetic field range on it (Table 2). The distance ranges from 1.6 cm to 6.7 cm while the intensity of the 
induced magnetic field in the ischemic lesion ranges from 1.0 to 2.2 mT. Then, the ischemic volume measured 
after the ELF-MF treatment has been superimposed to the dosimetry results, in order to correlate the volume 
changing of the injured area to the magnetic field experienced. No correlation was found between the intensity of 
the induced magnetic field in single ischemic lesions and the evolution of their volume.
Discussion
To our knowledge, this is the first study that explored the feasibility of ELF-MF stimulation in acute ischemic 
stroke patients. In a previous study on healthy volunteers, we have demonstrated that ELF-MF do not produce any 
side effect in humans11. In this pilot trial, we confirmed that such stimulation is safe and tolerable also in patients 
affected by acute stroke.
Indeed, during the 5-days ELF-MF exposure period, vital parameters remained stable and none of the patients 
experienced neurological worsening (change in NIHSS score), reported any AEs, or required to stop stimulation 
for any discomfort. These data were confirmed in a long follow-up period (12 months). Indeed, all the patients 
experienced a progressive improvement in clinical conditions (change in BI and mRS score). The safety of the 
ELF-MF exposure is also supported by brain MRI that ruled out any hemorrhagic transformation of ischemic 
lesion. Finally, we also considered a possible effect of ELF-MF on the evolution of ischemic lesion size. The nor-
mal evolution of the infarct volume on MRI within first months after stroke is matter of debate12,13. In our sample, 
we observe infarct growth in 2 out of 3 patients treated for 45 minutes per day while in the group stimulated for 
120 minutes, all the patients presented a reduction of the ischemic volume. These findings could suggest that 
ELF-MF exposure of appropriate duration influences the evolution of ischemic lesion toward a reduction of vol-
ume infarct.
Dosimetry study shows that, in all patients, the peak intensity of the magnetic field induced in the ischemic 
lesion was never below 1 mT, the minimum value able to trigger the upregulation of A2A receptors in preclini-
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4 120 5 3 0 0 0 35 25 100 100 100 3 3 0 0 0
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1 45 7,1 27,6 20,5 3,89 3.3 5.5 1.2 1.8
2 45 1,76 1,39 −0,37 0,79 5.7 6.7 1.0 1.2
3 45 11,8 16,0 4,2 1,35 1.6 5.6 1.2 2.2
4 120 25,83 23,15 −2,68 0,90 1.8 6.3 1.0 2.2
5 120 2,51 1,65 −0,86 0,66 2.7 4.5 1.5 1.9
6 120 5,85 3,12 −2,73 0,53 5.1 6.4 1.1 1.3
Table 2. Volumetric and dosimetric measures. DWI Volume PRE is the volume of the ischemic lesion, before 
treatment, on DWI images; T2 FLAIR Volume POST is the volume of the ischemic lesion, 1 month after 
treatment, on T2-weighted FLAIR images; Mismatch FLARI-DWI is the difference between the ischemic 
volume on FLAIR images after treatment and the ischemic volume on DWI images before treatment; FLAIR/
DWI rate is the ratio between the ischemic volume on FLAIR images after treatment and the ischemic volume 
on DWI images before treatment; Dmin - Dmax indicate the distances (minimum and maximum, respectively) 
of the ischemic lesion from the stimulating coil; Bmin - Bmax indicate the intensity of the magnetic field 
(minimum and maximum, respectively) induced in the ischemic lesion.
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exposure can exert a direct protective action toward hypoxic insult. Indeed, in neuron-like cells, such stimu-
lation partially restores hypoxia inducible factor-1𝛼 (HIF-1𝛼) activation and inhibits ROS production follow-
ing hypoxic incubation, while in microglial cells it significantly reduces ROS generation and proinflammatory 
cytokine release, crucial events in the exacerbation of ischemic condition7.
Although intriguing, the neuroprotective effect of ELF-MF needs to be confirmed because the present study 
was not specifically designed to demonstrate the efficacy of the proposed treatment. Indeed, the small sample 
size and the lack of a control group do not allow drawing any definite conclusion. On the other side, the use of 
an exposure system well-validated and already proved effective and safe in vitro5–7, in animal models8,9 and in 
healthy volunteers11 makes more robust our preliminary findings. The results of dosimetry study showing that the 
intensity of magnetic field induced in the ischemic lesion is compatible with a biological effect, further support 
experimental results.
The original design of our study included the recruitment of 9 patients divided in three cohorts with increas-
ing exposure duration: the first 3 patients for 45 min/day, the following 3 patients for 120 min/day and, the last 
3 patients for 240 min daily. Planned exposure of 240 min daily was not performed because it was considered 
unacceptable by the patients and treating physicians. However, the preliminary data obtained in the patients 
stimulated for 45 and 120 min/day clearly demonstrated the safety and tolerability of the ELF-MF and suggest a 
possible neuroprotective effect on ischemic lesion. For these reasons, we decided to prematurely stop this pilot 
trial and planned a prospective, randomized, placebo-controlled, double-blind study to specifically evaluate, 
Figure 2. Dosimetric results on exemplificative patient. (a) B field in ischemic lesion on the top and on slice 
perpendicular to the coil axis on the bottom; (b) on the left, geometrical comparison between the ischemic 
volumes before (green area) and after (light blue area) the magnetic field treatment, in the centre, B field on the 
pre-treatment injured volume; on the right, the same information overlapped with the geometric extension of 
the post-treatment area.
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in a large sample, the ability of ELF-MF (120 min/day) to promote recovery in acute ischemic stroke patients 
(NCT02767778). We think that this trial is justified especially given the low-cost and non-invasive nature of the 
treatment and the promising and converging evidence arising from preclinical studies5–9 and the results of the 
present pilot trial.
In conclusion, our study has demonstrated that ELF-MF stimulation is safe and tolerable in acute stroke 
patients. The main concerns of this study are the lack of a sham treated group and the small size of the enrolled 
sample of patients. A prospective, randomized, placebo-controlled, double-blind study will clarify whether 
ELF-MFs could represent a potential therapeutic approach in acute ischemic stroke.
Methods
The study complied with the Helsinki declaration and was approved by the local ethics committee (Università 
Campus Bio-Medico di Roma) and Italian Ministry of Health. Informed consent was obtained from all par-
ticipants. The study was registered with ClinicalTrials.gov, number NCT01941147 (September 9, 2013). Study 
protocol has been published14.
Patients. Patient recruitment took place between April 2013 and April 2014 at in-patient unit of the 
Neurology Department of Policlinico Universitario Campus Bio-Medico, Roma, Italy.
We planned to recruit 9 patients and to treat them according to the following dose-escalation scheme: the first 
3 patients for 45 min/day; in the absence of observed adverse events (AEs), the following 3 patients for 120 min/
day and, if AEs are still not observed, the last 3 patients for 240 min daily. Because of the exploratory nature of this 
pilot study, the planned sample size has not been statistically derived.
Eligible patients were >18 years with first mono-hemispheric ischemic stroke, onset of symptoms within 
48 hours and National Institutes of Health Stroke Scale (NIHSS) score >4. Exclusion criteria were: acute intrac-
ranial hemorrhage; previous ischemic or hemorrhagic stroke; history of seizure; contraindications to magnetic 
fields exposure (such as implanted metallic parts of implanted electronic devices or other metal in body); life 
expectancy <3 months; other serious illness or complex disease that may confound treatment assessment; women 
known to be pregnant, lactating or having a positive or indeterminate pregnancy test; simultaneous participation 
in another study.
Procedures. The system for delivering pulsed ELF-MF is described in Capone et al.11. It consists of 
a custom-made rectangular, flexible coil kept in place by a Velcro strap, upon the ischemic hemisphere. The 
Figure 3. The pulsed ELF-MF stimulation system. Generator (a), coil (b), and the helmet (c) for the positioning 
of the coil.
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magnetic pulse generator (B-01; IGEA, Carpi, Italy) supplied the coil with a single-pulsed signal at 75 ± 2 Hz, with 
a pulse duration of 1.3 ms. The peak intensity of the magnetic field was 1.8 ± 0.2 mT (Fig. 3).
The safety of the ELF-MF was evaluated by measuring the incidence of AEs and mortality throughout the 
stimulation period and along the 1-year follow-up. Questionnaires on AEs have been administered daily during 
the whole hospitalization and, after the discharge, at each outward control. Moreover, during the ELF-MF stim-
ulation, patients have been continuously monitored by a multimodal monitor that simultaneously assesses and 
displays ECG and the relevant vital parameters (respiratory rate, heart rate, blood pressure, pulse oximetry). The 
tolerability of the stimulation was evaluated by the number of subjects requesting to stop treatment.
Clinical evaluations have been performed by means of international well-validated scales such as NIHSS, 
Modified Rankin Scale (mRS), and Barthel Index (BI). The scores obtained at follow-up visits were compared 
with the baseline scores.
All MRI images were obtained with a 1.5 T scanner (Magnetom Symphony, Siemens Medical System, 
Erlangen, Germany). Sequences were performed in the same order with an initial T1-weighted sagittal local-
izer: T1-weighted spin-echo sequence in sagittal plane, T2-weighted turbo spin-echo sequence in coronal plane; 
diffusion-weighted sequence (DWI) in axial plane and T2-weighted Fluid-Attenuated Inversion Recovery 
(FLAIR) sequence in axial plane. DWI was obtained at three b values magnitude from 0 to 1000 s/mm2. 
Quantitative measure of volumetric ischemic area region was calculated before treatment on DWI images at 
high b value (1000 s/mm2) and after treatment on T2-weighted FLAIR images. Image analysis in-house software 
written in Matlab R2007a (The MathWorks, Inc., Natick, MA, USA) was used for measurement of ischemic lesion 
volumes. All the lesion areas on a section-by-section basis were segmented with a semiautomated region growing 
segmentation tool and then manual editing was performed. The semiautomated segmentation tool is based on 
a simple region-based image method15 that involves the selection of initial seed points and following examines 
Figure 4. Dosimetric methodology. (a) 3D ischemic model obtained starting from MRI data; (b) Insertion of 
the coil model and 3D ischemic model (patient specific) in the human head model.
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neighboring pixels of initial seed point and determines whether the pixel neighbors should be added to the region 
using a threshold of 20% of seed point signal intensity. An expert neuroradiologist reader blinded to clinical 
characteristics used this semiautomated technique for initial identification of all the lesions and a manual-editing 
tool for final corrections to the lesion borders. The number of pixels of segmented abnormal hyperintensity area 
were automatically summed and multiplied with the slice thickness and the pixel spacing to calculate the volumes 
of the acute ischemic lesions before treatment and of residual ischemic lesion after treatment. The rate between 
volumetric ischemic region evaluated on T2 weighted FLAIR images and on DWI scans (FLAIR/DWI) was per-
formed in addition to volumetric mismatch (FLAIR-DWI)16,17.
Dosimetry. The software used for the dosimetric analysis is Sim4Life v.1.2 (ZMT, Zurich MedTech AG), a 
simulation platform that can deal with medical image data obtained from MRI; in particular, with this software it 
is possible to convert the typical voxeled data obtained from MRI in volumes and smoothed surfaces and assign 
electric properties to them. The human head model was obtained from Duke of the ViP (v.1.0, ZMT AG);18 we 
selected a subdomain of 164 × 238 × 178 mm3, in order to include all the head structures.
The geometric model of the ischemic region was obtained directly from MRI images of the patients under-
gone to the treatment and elaborated with Matlab as previously explained. The ischemic volume was imported 
in Sim4Life v.1.2 and placed in Duke’s head model; the correct positioning has been achieved looking at the MRI 
images and estimating the distance of the ischemia from the skull and other brain structures. We assigned to the 
ischemic tissue the electric properties of the edema19, i.e. σ = 1.7 S/m and the same εr of the gray matter. The coil 
used in the simulation environment is a single turn rectangular coil of 14 × 10.6 cm; we chose a stimulation cur-
rent amplitude of 240 A because it is able to generate in the center of the coil a magnetic field intensity of about 2 
mT and to reproduce the same magnetic field of the experimental set up. The single turn has been then warped 
in order to simulate the coil properties of being adaptable to the head shape; this warping has been obtained by 
computing the mean head curvature in the coronal plane. Then, the coil has been placed as close as possible to the 
head and in order to have the ischemic volume on the coil axis. Figure 4 shows the final geometry of the model 
for one patient, the same procedure has been followed for all the patients. Since the presence of the head struc-
tures, including ischemia, does not alter the magnetic distribution, all the tissues experience a magnetic field that 
depends only on the distance from the coil center and the current intensity that feeds the coil. For this reason, the 
higher is the distance from the coil, the lower is the field intensity.
Data Availability. All data generated or analysed during this study are included in this published article.
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